Merck & Co Inc

NYSE:MRKUnited States

Today

Show headlines and story abstract

• Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating, from 7 hours ago by MT Newswires

  7 hours ago by MT Newswires
  Companies Mentioned: MRK
  12:52 PM EDT, 04/25/2024 (MT Newswires) -- Merck & Co. (MRK) has an average rating of outperform and price targets ranging from $114 to $148, according to analysts polled by Capital IQ. (MT Newswires covers equity, commodity and economic research fr...

• Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump, from 7 hours ago by MT Newswires

  7 hours ago by MT Newswires
  Companies Mentioned: HMC, IBM, LUV, MRK, BX, NSC, KKR, AMZN, META, AZN, CAT, CMCSA
  12:36 PM EDT, 04/25/2024 (MT Newswires) -- All three major Wall Street indexes were down in late-morning trading as investors processed a GDP report that showed slower-than-anticipated growth with persistently high inflation and earnings misses fro...

• DJ Merck Shares Climb After Higher-Than-Expected Sales of Cancer Drug Keytruda -- WSJ, from 10 hours ago by Dow Jones

  10 hours ago by Dow Jones
  Companies Mentioned: MRK
  
  By Peter Loftus
  
  Shares of U.S. drugmaker Merck are up about 2.5% in premarket trading after reporting that its blockbuster cancer drug Keytruda fueled a higher-than-expected increase in quarterly sales and earnings.
  

• Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat, from 11 hours ago by MT Newswires

  11 hours ago by MT Newswires
  Companies Mentioned: MRK
  08:27 AM EDT, 04/25/2024 (MT Newswires) -- Merck (MRK) on Thursday recorded better-than-expected first-quarter results boosted by sales of cancer immunotherapy Keytruda and human papillomavirus vaccine Gardasil, prompting the pharmaceutical giant to...

• Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised, from 12 hours ago by MT Newswires

  12 hours ago by MT Newswires
  Companies Mentioned: MRK
  07:00 AM EDT, 04/25/2024 (MT Newswires) -- Merck (MRK) reported Q1 non-GAAP earnings Thursday of $2.07 per share, up from $1.40 a year ago. Analysts polled by Capital IQ expected $1.92. Sales for the quarter ended March 31 were $15.78 billion, up fr...